首页> 外国专利> Treatment of Multiple Sclerosis With Combination of Laquinimod and Dimethyl Fumarate

Treatment of Multiple Sclerosis With Combination of Laquinimod and Dimethyl Fumarate

机译:拉喹莫德联合富马酸二甲酯治疗多发性硬化症

摘要

This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with DMF. This invention also provides a package comprising laquinimod and DMF for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with DMF in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides a pharmaceutical composition comprising laquinimod and DMF for use in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and DMF in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.
机译:本发明提供了一种治疗患有多发性硬化症或表现出临床分离的综合症的受试者的方法,该方法包括向该受试者施用拉喹莫德作为DMF或与DMF组合的附加疗法。本发明还提供了包含拉喹莫德和DMF的包装,用于治疗患有多发性硬化症或表现出临床分离的综合症的受试者。本发明还提供了拉喹莫德,其用作附加疗法或与DMF组合用于治疗患有多发性硬化症或表现出临床分离的综合征的受试者。本发明还提供了包含拉喹莫德和DMF的药物组合物,用于治疗患有多发性硬化症或表现出临床分离的综合症的受试者。本发明进一步提供了拉喹莫德和DMF在制备用于治疗患有多发性硬化症或表现出临床分离的综合征的受试者的组合中的用途。

著录项

  • 公开/公告号US2018050031A1

    专利类型

  • 公开/公告日2018-02-22

    原文格式PDF

  • 申请/专利权人 TEVA PHARMACEUTICAL INDUSTRIES LTD.;

    申请/专利号US201715803017

  • 发明设计人 JOEL FLAXMAN KAYE;

    申请日2017-11-03

  • 分类号A61K31/4704;A61K45/06;A61K31/225;A61K31/47;

  • 国家 US

  • 入库时间 2022-08-21 13:02:58

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号